Company
Fujian Haixi Pharmaceuticals Co., Ltd.
Fujian Haixi Pharmaceutical Co., Ltd. (“Haixi Pharmaceutical”, 02637.HK) was founded in 2012 as a commercial-stage innovative pharmaceutical company covering the entire industrial chain of R&D, clinical research, manufacturing and commercialization. The company was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited on October 20, 2025, and was included in the Hang Seng Stock Connect Hong Kong on March 9, 2026.
Adhering to the development philosophy of “Generics Empower Innovation, Innovation Drives the Future”, the company pursues a coordinated strategy of generic drugs and innovative drugs.
In the field of generic drugs, the company focuses on the R&D of first-to-file generics, difficult-to-make generics and high-value generics. As of March 2026, 15 products have been approved for launch. Four core products, namely Mosapride Citrate Tablets (Anbili?), Cinacalcet Hydrochloride Tablets (Ruiantuo?), Amlodipine Besylate and Atorvastatin Calcium Tablets (Haihuitong?) and Hydroxychloroquine Sulfate Tablets (Saixifu?), have successfully won bids in the 4th, 5th, 8th and 10th rounds of national centralized drug procurement respectively, forming a stable revenue stream to sustain the R&D of innovative drugs.
For innovative drugs, the company has independently developed the MultiSel Opt small-molecule innovative drug R&D platform, which enables a single drug molecule to selectively act on multiple protein targets for synergistic therapeutic mechanisms. HXP056, an oral small-molecule drug developed on this platform, is currently in Phase I/II clinical development. It is intended for the treatment of retinal diseases related to neovascularization, including wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO), and is expected to become the world’s first oral innovative drug for these indications. The oncology drug C019199 is planned to initiate a Phase III clinical trial for osteosarcoma in China in the first half of 2026, aiming to provide a new therapeutic option for osteosarcoma patients.
Led by Dr. Xinshan Kang , the company has assembled a high-level talent team and strengthened industry-university-research cooperation. It has been recognized as a National High-Tech Enterprise, a National Specialized, Refined, Differential and Innovative “Little Giant” Enterprise, and the first enterprise in Fujian Province to obtain a Drug Production License (Category B), and holds more than 30 invention patents.
Looking ahead, Haixi will continue to uphold the corporate spirit of “Hard-Working with Result-Oriented”, adhere to its core values of“Innovation, Integrity, Sharing & Goodwill”. With both a down-to-earth approach and visionary ambition, the company will keep expanding its portfolio of globally competitive innovative medicines, striving to realize its vision: “Best Medicine Made Available to People.”
